1907 related articles for article (PubMed ID: 30564308)
21. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
Rodloff AC; Dowzicky MJ
Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271
[TBL] [Abstract][Full Text] [Related]
23. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).
Farrell DJ; Turnidge JD; Bell J; Sader HS; Jones RN
J Infect; 2010 Jun; 60(6):440-51. PubMed ID: 20361999
[TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
Reinert RR; Low DE; Rossi F; Zhang X; Wattal C; Dowzicky MJ
J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
[TBL] [Abstract][Full Text] [Related]
27. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
Liu JW; Ko WC; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Chen YH; Lu PL; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1414-7. PubMed ID: 22155819
[TBL] [Abstract][Full Text] [Related]
28. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016.
Zhang F; Li Y; Lv Y; Zheng B; Xue F
J Glob Antimicrob Resist; 2019 Jun; 17():276-282. PubMed ID: 30611932
[TBL] [Abstract][Full Text] [Related]
29. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Biedenbach DJ; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Zhanel GG; DeCorby M; Laing N; Weshnoweski B; Vashisht R; Tailor F; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; McCracken M; Mulvey MR; Johnson J; ; Hoban DJ
Antimicrob Agents Chemother; 2008 Apr; 52(4):1430-7. PubMed ID: 18285482
[TBL] [Abstract][Full Text] [Related]
31. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
[TBL] [Abstract][Full Text] [Related]
33. In-vitro activity of tigecycline and comparator agents against common pathogens: Indian experience.
Veeraraghavan B; Poojary A; Shankar C; Bari AK; Kukreja S; Thukkaram B; Neethimohan RG; Bakhtavachalam YD; Kamat S
J Infect Dev Ctries; 2019 Mar; 13(3):245-250. PubMed ID: 32040455
[TBL] [Abstract][Full Text] [Related]
34. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
Dowzicky MJ; Chmelařová E
Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
[TBL] [Abstract][Full Text] [Related]
35. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
36. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
38. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
39. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
Hoban DJ; Reinert RR; Bouchillon SK; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 May; 14():27. PubMed ID: 25958201
[TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
